BEIJING: China has approved three COVID-19 vaccine candidates for clinical trials, said an official with the Ministry of Science and Technology (MOST) on Tuesday.
An adenovirus vector vaccine, developed by a research team led by Chen Wei, an academician with the Chinese Academy of Engineering and a researcher at the Institute of Military Medicine under the Academy of Military Sciences, was the first to be approved to enter clinical trials, said Wu Yuanbin, director-general of science and technology for social development with the MOST, at a press conference.
The first phase of the clinical trial was completed at the end of March, and the second phase started on April 12.
It is the first COVID-19 vaccine in the world that has entered the second phase of clinical trials, according to the World Health Organization.
Accompanied by his daughter, Xiong Zhengxing, an 84-year-old man in Wuhan, was vaccinated on April 13, becoming the oldest volunteer in the second phase of the clinical trial.
Compared with the first phase, the second phase has removed the age ceiling to enroll volunteers over 60.
As the elderly make up a high percentage of the severely ill COVID-19 patients, the vaccine should build a safety shield for them, Chen said.
Taking the modified defective adenovirus as the vector, the vaccine carries the gene of the coronavirus spike protein, the major surface protein used by the virus to bind to a receptor to invade cells, so that the subject’s body will produce the immunological memory of the protein. When the real coronavirus attacks, the body will identify its spike protein and stop its invasion, according to Chen.
The 108 volunteers who completed the first phase of the clinical trial on March 27 have ended centralized medical observation and are in good condition.
The second phase will recruit 500 volunteers and introduce the placebo control group to further evaluate the immunogenicity and safety of the vaccine. As of 5 p.m. on April 13, 273 volunteers had been vaccinated.
An inactivated vaccine candidate developed by the Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and the Wuhan Institute of Virology under the Chinese Academy of Sciences was approved for clinical trials on April 12, Wu said.
Another inactivated vaccine candidate developed by Sinovac Research and Development Co., Ltd., a company based in Beijing, was approved on April 13, he added.
Using killed pathogenic microorganisms to enhance the immunogenicity, inactivated vaccines have advantages of mature production process, controllable quality standards and wide protection range, according to Wang Junzhi, an academician with the Chinese Academy of Engineering.
To produce the vaccine, researchers cultivated live viruses on a large scale in P3 laboratories, which have relatively high biosafety standards, Wang said.
Experts have been invited to give whole-process direction in the preclinical animal experiments of the vaccines, including acute toxicity experiments, repeated toxicity experiments and immunogenicity experiments, he said.
Sample vaccines for clinical trials have passed inspections by the Food and Drug Administration and the National Institutes for Food and Drug Control, he added.
China has laid a solid foundation for research into inactivated vaccines over recent years. Inactivated vaccines have been widely used to fight hepatitis A, influenza, hand-foot-and-mouth disease and poliomyelitis, he said.
The safety and effectiveness of inactivated vaccines can be judged by internationally accepted standards, Wu said.
FIVE APPROACHES TO VACCINES
Wu said China adopted five technological approaches to develop COVID-19 vaccines, including inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza viruses as vectors.
Aside from the adenovirus vector vaccine and inactivated vaccine, vaccines of other technical routes are also advancing rapidly.
The strains have been constructed and quality inspection methods have been set up for the vaccine using attenuated influenza viruses. Pilot production, animal poison attack experiments and safety evaluation experiments will be carried out in the same period, according to Wu.
The recombinant protein vaccine has completed the construction of virus species, and is carrying out the genetic stability inspection, animal experiments and safety evaluation, Wu said.
The nucleic acid vaccine has also entered the research stage of animal experiments and safety evaluation, and the preparation and quality inspection of samples for clinical trials are carried out simultaneously, he said.
These vaccine candidates are expected to apply for clinical trials in April and May, he said.
China has accelerated the approval procedures for COVID-19 vaccines that have demonstrated their safety and efficacy. The seamless connection between research and approval is the major reason behind the fast development of vaccines, according to Wang.
Stressing safety as a priority, Wang said clinical trials of a vaccine usually undergo three phases.
The first phase usually enrolls dozens of volunteers to test the safety of the vaccine and the human body’s tolerance to different doses. The second phase will expand the subjects to hundreds of volunteers to further verify its efficacy and safety. The third phase may involve thousands or even tens of thousands of people and last for an epidemic cycle to finally determine its effectiveness and provide a scientific basis for the approval for clinical use, Wang said.
“We look forward to seeing a breakthrough in China’s vaccine research and development, so that safe and effective vaccines can be put to use as soon as possible,” he said. (Agencies)
